ROSEN CHRISTER
Known title: CEO and ChairmanCIK: 0000902453
ROSEN CHRISTER's purchase track record
ROSEN CHRISTER has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/27/2025 | JUNS | $12K | +51.4% | +8.6% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JUNS | ▲ Buy | Open Market | 500 | $505 | 7/1/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 3,100 | $3K | 7/1/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 1,000 | $980 | 6/30/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 2,000 | $2K | 6/30/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 1,450 | $1K | 6/30/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 700 | $721 | 6/30/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 1,500 | $2K | 6/30/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 1,000 | $1K | 6/30/2025 | View on chart |
| JUNS | ▲ Buy | Open Market | 166 | $176 | 6/27/2025 | View on chart |
| JUNS | ▲ Buy | Option Exercise | 497,396 | $0 | 6/2/2025 | View on chart |
| JUNS | ▲ Buy | Option Exercise | 476,070 | $0 | 6/2/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
JUNS doses first patient in Phase 2a Parkinson’s trial
Jupiter Neurosciences reported that the first participant has been dosed in its Phase 2a RESET trial of JOTROL for Parkinson’s disease. The company also said it is reviewing strategic options to enhance shareholder value. The trial start follows recent mixed movement in healthcare stocks, but the dosing event provides a specific catalyst for the company.
JUNS doses first patient in Phase 2a Parkinson’s trial. Jupiter Neurosciences reported that the first participant has been dosed in its Phase 2a RESET trial of JOTROL for Parkinson’s disease. The company also said it is reviewing strategic options to enhance shareholder value. The trial start follows recent mixed movement in healthcare stocks, but the dosing event provides a specific catalyst for the company.